Can Johnson & Johnson’s oral Icotyde compete with biologics in psoriatic arthritis?
Icotyde achieved 58% ACR20 in Phase 3 psoriatic arthritis, but the 400 mg dose added no benefit. Can Johnson & Johnson challenge biologics?
Pharma & Biotech
Pharma & Biotech
Johnson & Johnson reports long-term ICOTYDE efficacy and safety in plaque psoriasis
Johnson & Johnson reports two-year ICOTYDE psoriasis results, with over 72% achieving PASI 90. See what the data mean for treatment.
Pharma & Biotech
Why Bristol Myers Squibb’s Sotyktu approval could reshape the oral psoriatic arthritis race
A new EU approval is only the first hurdle. Sotyktu now faces Europe’s tougher test: payer access, sequencing, and real-world uptake.
Pharma & Biotech
Can Takeda’s zasocitinib change the plaque psoriasis treatment ladder after Phase 3 wins?
Takeda’s zasocitinib posted strong Phase 3 psoriasis data. Read what it changes for TYK2 competition, regulation, and oral treatment strategy.
Pharma & Biotech
Bristol Myers Squibb expands Sotyktu label. Will TYK2 inhibition challenge biologics in psoriatic arthritis?
FDA approves Bristol Myers Squibb’s Sotyktu for psoriatic arthritis. Discover what TYK2 inhibition means for autoimmune treatment and future rheumatology drugs.